Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | CNR1 | P21554 | 3/20 | 0.33 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | USP14 | P54578 | 1/20 | 0.32 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5582864 | 0.85 | JAK2 (0.43) | NTRK1 | |
| SCHEMBL25097632 | 0.81 | NTRK1 (0.40) | CNR2CNR1MAP2K4USP14NTRK1 | |
| SCHEMBL16534159 | 0.78 | KDM4E (0.50) | NTRK1LMNARAB9AMAPK10SMN1; SMN2 | |
| SCHEMBL298834 | 0.76 | CA12 (0.40) | HSD17B10 | |
| SCHEMBL2660555 | 0.76 | NTRK1 (0.44) | NTRK1SMN1; SMN2 | |
| SCHEMBL14755242 | 0.74 | MAP2K4 (0.35) | MAP2K4NTRK1 | |
| SCHEMBL25097633 | 0.72 | NOS1 (0.45) | RAB9A | |
| SCHEMBL14737842 | 0.72 | CNR2 (0.36) | CNR2CNR1USP14 | |
| SCHEMBL13375276 | 0.71 | MAP2K4 (0.49) | MAP2K4NTRK1 | |
| SCHEMBL1623188 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2023-03-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230071620-A1 | PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CNR2 1208/4885CNR1 1311/4885MAP2K4 1732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.